FI116659B - Yhdisteiden käyttö valmistettaessa lääkettä multippeliskleroosin (MS) ja muiden myeliinikatotilojen hoitoon - Google Patents

Yhdisteiden käyttö valmistettaessa lääkettä multippeliskleroosin (MS) ja muiden myeliinikatotilojen hoitoon Download PDF

Info

Publication number
FI116659B
FI116659B FI971290A FI971290A FI116659B FI 116659 B FI116659 B FI 116659B FI 971290 A FI971290 A FI 971290A FI 971290 A FI971290 A FI 971290A FI 116659 B FI116659 B FI 116659B
Authority
FI
Finland
Prior art keywords
lofepramine
phenylalanine
antidepressant
use according
treatment
Prior art date
Application number
FI971290A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI971290A0 (fi
FI971290A (fi
Inventor
Cari Loder
Original Assignee
Amarin Neuroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9420116A external-priority patent/GB9420116D0/en
Priority claimed from GBGB9508482.8A external-priority patent/GB9508482D0/en
Application filed by Amarin Neuroscience Ltd filed Critical Amarin Neuroscience Ltd
Publication of FI971290A0 publication Critical patent/FI971290A0/fi
Publication of FI971290A publication Critical patent/FI971290A/fi
Application granted granted Critical
Publication of FI116659B publication Critical patent/FI116659B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
FI971290A 1994-10-05 1997-03-26 Yhdisteiden käyttö valmistettaessa lääkettä multippeliskleroosin (MS) ja muiden myeliinikatotilojen hoitoon FI116659B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9420116A GB9420116D0 (en) 1994-10-05 1994-10-05 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions
GB9420116 1994-10-05
GB9502361 1995-02-07
GB9508482 1995-04-26
GBGB9508482.8A GB9508482D0 (en) 1995-04-26 1995-04-26 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions, and the product
PCT/GB1995/002361 WO1996011009A1 (en) 1994-10-05 1995-10-05 Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound

Publications (3)

Publication Number Publication Date
FI971290A0 FI971290A0 (fi) 1997-03-26
FI971290A FI971290A (fi) 1997-06-02
FI116659B true FI116659B (fi) 2006-01-31

Family

ID=26305745

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971290A FI116659B (fi) 1994-10-05 1997-03-26 Yhdisteiden käyttö valmistettaessa lääkettä multippeliskleroosin (MS) ja muiden myeliinikatotilojen hoitoon

Country Status (19)

Country Link
US (2) US6096737A (cs)
EP (1) EP0784476B1 (cs)
JP (1) JPH10508583A (cs)
AT (1) ATE227124T1 (cs)
AU (1) AU710339B2 (cs)
CA (1) CA2200761C (cs)
CZ (1) CZ293873B6 (cs)
DE (1) DE69528773T2 (cs)
DK (1) DK0784476T3 (cs)
ES (1) ES2184808T3 (cs)
FI (1) FI116659B (cs)
HU (1) HU225493B1 (cs)
IS (1) IS1956B (cs)
NO (1) NO314486B1 (cs)
NZ (1) NZ293642A (cs)
PL (1) PL181802B1 (cs)
PT (1) PT784476E (cs)
SK (1) SK281932B6 (cs)
WO (1) WO1996011009A1 (cs)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0942751T3 (da) * 1996-07-05 2002-12-02 Wwk Trust Præparater til behandling af perifere nuropatier indeholdende antidepressiver og/eller monoaminoxidase-inhibitorer og/eller vitamin B12 og/eller prekursere til eller inducere af en neurotransmitter
GB9617990D0 (en) 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
EP0835660A1 (en) * 1996-10-14 1998-04-15 Gaston Edmond Filomena Merckx Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions
US7232830B2 (en) * 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
GB9904252D0 (en) * 1999-02-24 1999-04-21 Worsley Andrew P Composition for the treatment of pain
GB9906808D0 (en) * 1999-03-24 1999-05-19 Kilgowan Limited Formulation for treatment of pain
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
WO2002011676A2 (en) * 2000-08-04 2002-02-14 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20020147206A1 (en) * 2001-04-05 2002-10-10 Pfizer Inc. Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US6833142B2 (en) * 2002-03-14 2004-12-21 Duane Bennett Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions
EP1571970B1 (en) 2002-10-02 2011-08-17 DMI Biosciences, Inc. Diagnosis and monitoring of diseases
EP1599212A4 (en) * 2003-02-14 2006-02-08 Combinatorx Inc POLYTHERAPY FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISORDERS
WO2004103304A2 (en) * 2003-05-15 2004-12-02 Dmi Biosciences, Inc. Treatment of t-cell mediated diseases
GB0313630D0 (en) * 2003-06-12 2003-07-16 Wwk Trust The Compositions for the enhanced treatment of depression
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
ATE552832T1 (de) 2006-02-24 2012-04-15 Shire Llc Antidepressivum-propharmaka
EP2300011A4 (en) * 2008-05-27 2012-06-20 Dmi Life Sciences Inc METHODS AND THERAPEUTIC COMPOUNDS
WO2011011594A2 (en) * 2009-07-23 2011-01-27 Shriners Hospitals For Children Intracellular toll-like receptors pathways and axonal degeneration
JP2013537195A (ja) 2010-09-07 2013-09-30 ディエムアイ アクイジション コーポレイション 疾患の治療
KR102032400B1 (ko) 2011-10-10 2019-10-15 앰피오 파마슈티컬스 인코퍼레이티드 퇴행성 관절 질환의 치료
CN103841934A (zh) 2011-10-10 2014-06-04 安皮奥制药股份有限公司 增强免疫耐受的可植入的医疗装置及其制造与植入方法
EP2771007B1 (en) 2011-10-28 2018-04-04 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
WO2014145729A2 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
EP4066836A1 (en) 2014-08-18 2022-10-05 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
WO2016209969A1 (en) 2015-06-22 2016-12-29 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
GB2544630A (en) 2015-11-19 2017-05-24 The Wwk Trust Combinations for the treatment of dementia, and the enhancement of cognitive function
CA3041358A1 (en) * 2016-10-25 2018-05-03 Uti Limited Partnership Treatment for progressive multiple sclerosis
EP3615053A4 (en) 2017-04-25 2021-07-14 Temple Otorongo LLC PHARMACEUTICAL COMPOSITION CONSISTING OF TRYPTOPHAN AND A PHYLLOKININ DERIVATIVE FOR USE IN THE TREATMENT OF PSYCHIATRIC AND PSYCHOLOGICAL DISORDERS
EP3431491A1 (en) * 2017-07-18 2019-01-23 Centre National De La Recherche Scientifique Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1497306A (en) * 1975-07-03 1978-01-05 Leo Ab Preparation of lofepramine and its hydrochloride
GB2082910A (en) * 1980-08-28 1982-03-17 Berk Pharmaceuticals Ltd Anti-depressant compositions
US4409243A (en) * 1981-11-09 1983-10-11 Julian Lieb Treatment of auto-immune and inflammatory diseases
GB2129299A (en) * 1982-11-09 1984-05-16 Alec James Coppen Pharmaceutical compositions
DE3519687A1 (de) * 1985-06-01 1986-12-04 Veit Arend Aminosaeuren enthaltendes arzneimittel
US4650789A (en) * 1985-10-15 1987-03-17 Commonwealth Medical Corporation Of America Method and composition for increasing production of serotonin
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
DE4204102C2 (de) * 1992-02-12 1998-09-24 Kragler Peter Arzneimittel zur Behandlung und/oder Prophylaxe von AIDS und anderen verwandten Erkrankungen

Also Published As

Publication number Publication date
PT784476E (pt) 2003-03-31
US6569850B1 (en) 2003-05-27
CA2200761A1 (en) 1996-04-18
NO314486B1 (no) 2003-03-31
AU710339B2 (en) 1999-09-16
ATE227124T1 (de) 2002-11-15
DE69528773T2 (de) 2003-09-04
AU3612695A (en) 1996-05-02
PL181802B1 (en) 2001-09-28
NZ293642A (en) 1998-10-28
SK43897A3 (en) 1998-08-05
DE69528773D1 (de) 2002-12-12
CA2200761C (en) 2008-02-26
EP0784476A1 (en) 1997-07-23
JPH10508583A (ja) 1998-08-25
FI971290A0 (fi) 1997-03-26
ES2184808T3 (es) 2003-04-16
FI971290A (fi) 1997-06-02
DK0784476T3 (da) 2003-03-17
CZ99597A3 (en) 1997-11-12
WO1996011009A1 (en) 1996-04-18
NO971539L (no) 1997-04-04
HUT77380A (hu) 1998-04-28
IS4454A (is) 1997-03-26
HU225493B1 (en) 2007-01-29
SK281932B6 (sk) 2001-09-11
PL319830A1 (en) 1997-09-01
EP0784476B1 (en) 2002-11-06
IS1956B (is) 2004-11-15
CZ293873B6 (cs) 2004-08-18
NO971539D0 (no) 1997-04-04
US6096737A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
FI116659B (fi) Yhdisteiden käyttö valmistettaessa lääkettä multippeliskleroosin (MS) ja muiden myeliinikatotilojen hoitoon
US10786469B2 (en) Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11273133B2 (en) Bupropion as a modulator of drug activity
Glassman et al. Potentiation of a monoamine oxidase inhibitor by tryptophan
Mavissakalian et al. Imipramine dose-response relationship in panic disorder with agoraphobia: Preliminary findings
CN112437659B (zh) 用于治疗抑郁症的右美沙芬和安非他酮的组合
CN115697314A (zh) 安非他酮和右美沙芬组合用于治疗神经病症的用途
JP2008201799A (ja) コカイン依存症治療用薬剤
JP2004519461A5 (cs)
JP2004519461A (ja) アルコール依存症治療用薬剤の製造時におけるフルマゼニルの使用
US10925879B2 (en) Methods of treating developmental disorders and/or seizure disorders with etifoxine
JP2003522112A5 (cs)
KR20230131927A (ko) 신경 정신 질환에 대한 항우울제와 덱스트로메토르판의조합
AU2022374097A1 (en) 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression
EP3585380A1 (en) Methods of treating seizure disorders
Qureshi et al. Pharmacotherapies of addiction
Dinan Lithium potentiation and treatment of refractory depression
SHERMAN Injectable Naltrexone Shows Improved Efficacy
MXPA06007770A (en) Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
AU2006200922A1 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: AMARIN NEUROSCIENCE LIMITED

Free format text: AMARIN NEUROSCIENCE LIMITED

FG Patent granted

Ref document number: 116659

Country of ref document: FI